New York, USA – December 29, 2022 – BOC Sciences today announced the release of premium GalNAc-siRNA conjugation services to further support the delivery of siRNA drugs to the liver.
Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence production of target mRNA in the kidney Megalin-binding genetic medicines are ...
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting ...
ProteinQure announced new preclinical results today, demonstrating efficient delivery of small interfering RNA (siRNA) to the central nervous system (CNS) in non-human primates. Using intrathecal ...
A startup focused on developing oligonucleotide-based silent RNA treatments for systemic and renal diseases is emerging from stealth mode, launching with $100 million in combined seed and ...
PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587), announced the achievement of a preclinical development milestone in ...
PHILADELPHIA--(BUSINESS WIRE)-- Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its ...
Variations in conjugation chemistry conditions can lead to differences in stoichiometries and, ultimately, impact drug safety and efficacy. Therefore, there is an urgent need to measure multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results